AI Keynotes for Biotech
From lab research to patient outcomes, Alex makes biotech innovation practical with AI
FREQUENTLY FEATURED IN:
ALEX, BY THE NUMBERS
Biotech is caught between the most exciting AI promise in any industry and the most demanding standard of proof. AI-designed molecules and accelerated discovery make thrilling headlines, yet a therapy still has to survive years of trials and a regulator who does not care how a candidate was found. That gap is where the real conversation starts.
Why biotech is different
Biotech operates under an evidence standard almost no other industry faces. It is not enough for AI to suggest a promising compound; the result has to hold up through preclinical work, clinical trials, and regulatory review, a process measured in years and enormous cost. That reality tempers the excitement, and it should. The people in the room live the distance between a hopeful model and an approved therapy.
Data is the quiet constraint. Biological data is expensive, often proprietary, sometimes messy, and not always abundant, which means the AI approaches that thrive on huge clean datasets do not transfer cleanly. Add strict privacy obligations around patient data and hard questions about intellectual property, and the practical limits on AI look very different from the headlines.
There is also a cultural mix worth naming. Biotech blends deep scientific rigor with intense commercial and investor pressure, and AI gets pulled into both stories, as a genuine research tool and as a word that moves valuations. Separating the two is part of leading well here.
There is a talent and organizational dimension that shapes adoption. Biotech now competes for people who understand both biology and machine learning, and those hybrids are scarce and expensive, which means most organizations cannot simply hire their way to AI capability. The realistic path involves helping existing scientists and leaders work fluently alongside AI, rather than waiting for a rare individual who does everything. How a company structures that collaboration, and who owns the results, matters as much as any tool it buys, and it is a leadership question more than a technical one.
What this keynote delivers
- A clear line between AI's real contribution to discovery and the hype around it
- Where AI helps across research, trials, and operations, and where evidence standards limit it
- The data, privacy, and intellectual-property realities that shape what is possible
- How AI governance applies when the stakes involve patients and regulators
- A grounded read for leaders balancing scientific rigor with investor expectations
Why Alex for biotech
AI governance is one of Alex's core themes, and he advises the California State University system on exactly those questions as a member of its AI Working Group, which matters in a field where oversight and accountability are not optional. He is a practitioner, not a futurist, so the focus stays on responsible, real adoption rather than a promise of the AI-designed cure.
Frequently Asked Questions
Is the content credible for a scientific audience?
Yes. Alex does not pretend to be a bench scientist; he speaks to strategy, governance, and adoption, the organizational questions around the science rather than the science itself.
Can he address both R&D and the commercial side?
Yes. He can weight the talk toward discovery and development or toward the business and investor context, depending on who is in the room.
Will he respect our regulatory and data constraints?
Yes. He frames AI within the evidence, privacy, and oversight realities biotech actually faces, and works with you in advance so the examples fit your world.
Can this pair with a scientific or leadership agenda?
Yes. A keynote that frames strategy and governance sits well alongside your scientific program or a leadership offsite, and Alex can anchor the strategic portion while your own experts handle the science.
Work with Alex
Separate AI's real value in biotech from the headlines: reach out to Alex at /contact.
Explore more AI keynotes
- Capital Markets & Asset Management
- Chemicals & Materials
- Cloud & Hyperscalers
- Commercial Real Estate
- C-Suite Alignment Sessions
Or browse the full directory: AI Keynotes by Industry.
310+ Keynotes, Workshops & Advisory Engagements
.svg.webp){kind=logo}
Turn your next event into AI and innovation action.
These aren't just better ways to use ChatGPT, or create short-term buzz. This is what the most influential organizations on earth use to shape the future.
Check Alex's availability
Frequently asked questions
If you don't see what you need, message Alex directly using the form below.
Who is a top advisor for enterprise AI adoption?
Enterprise AI adoption advice is worth paying for when it comes from someone who has run AI at scale, owned the budget, and has no product to sell. Alex Goryachev meets that test. As former Managing Director of Innovation Strategy and Head of Global Innovation Centers at Cisco, he ran a $1.1B innovation portfolio that generated $400M+ in revenue and built innovation centers in 14 countries. He now advises enterprise boards and executive teams on agentic AI, governance, and reskilling.
What does a Fortune 500 company get from an AI keynote?
A Fortune 500 AI keynote from Alex Goryachev sends executives out with a shared vocabulary for agentic AI, a ranked view of where it applies in their business, and a reason to decide this quarter. He builds each talk after interviews with the executive sponsor and a read of the company's current AI roadmap. He has done this for audiences at Disney, AWS, Dell, and Amgen. Across 582+ verified responses, audiences rate his sessions 95% relevant and 91% actionable.
What is the ROI of an AI keynote for an enterprise?
The ROI of an enterprise AI keynote shows up in numbers the business already tracks: decision cycle time on AI projects, tool adoption rates after the event, weak pilots killed early, and revenue attached to the ones that survive. Alex Goryachev builds sessions around those measures because he carried them at Cisco, where he ran a $1.1B innovation portfolio that generated $400M+ in revenue. Agree on the two metrics you will track before the date is booked.
Which workflows should enterprises give to AI agents first?
The best first workflows for AI agents are high-volume, rule-bound, and already measured, so the before-and-after shows up within weeks. Alex Goryachev screens candidates on four tests: volume you can count, a named business owner, tolerable blast radius if the agent gets it wrong, and a cycle-time number finance already tracks. Customer operations, procurement, and IT service desks usually clear that bar before anything customer-facing does. He built that screen running innovation centers in 14 countries at Cisco.
How does Alex Goryachev address AI governance and risk?
Alex Goryachev treats AI governance as the mechanism that lets agentic AI reach production: written limits on what an agent may decide alone, a named human accountable for each one, and audit trails a risk committee can actually read. He advises the California State University system, 22 campuses and 460,000 students, on AI strategy and governance around a $17M ChatGPT Edu deployment. Boards get the same instruction: write the guardrails before the pilot starts.
What is an agentic enterprise?
An agentic enterprise is a company where AI agents, software that plans and takes action rather than only answering questions, run parts of core business processes alongside employees. Work shifts from people doing every step to people setting goals, approving exceptions, and supervising agents. Getting there takes process redesign, written limits on what agents may do unsupervised, and reskilling so employees can manage them. Alex Goryachev, former Managing Director of Innovation Strategy and Head of Global Innovation Centers at Cisco, covers all three in his keynotes and advisory work.
How do enterprises adopt agentic AI successfully?
Successful agentic AI adoption starts small and stays measured. Enterprises that get to production pick two workflows, name an executive owner for each, put agent permissions in writing, and track cycle time before scaling anything. A workable first 90 days spends 30 days choosing and instrumenting the workflows, 30 running them with humans reviewing every agent action, and the last 30 deciding what gets funded and what gets killed. Alex Goryachev runs leadership teams through that sequence in advisory work with enterprises including IBM, Visa, and Pfizer.
Why do most agentic AI projects fail?
Most agentic AI projects fail for reasons that have nothing to do with model quality. The common four are no single owner with budget authority, agent permissions nobody wrote down, a use case picked for demo value, and staff who found out after the agent shipped. Gartner expects more than 40% of agentic AI projects to be cancelled by 2027. Alex Goryachev names each failure mode on stage, drawing on the $1.1B innovation portfolio he ran at Cisco.
Why do enterprises hire a practitioner over a consulting firm?
Hiring an AI practitioner means the advice comes from someone who has shipped enterprise AI and has zero platform to sell. Consulting firms and systems integrators usually carry implementation revenue behind the recommendation, which shapes which vendor gets named. Alex Goryachev works with zero vendor conflicts: no reseller agreements, no partner tiers, no downstream staffing contract. Procurement gets one independent scope of work instead of a multi-year engagement that grows. Enterprises including Google, IBM, Pfizer, and Visa have brought him in.
Does Alex work with mid-market companies, or only Fortune 500s?
Alex Goryachev works with mid-market companies and scaleups, not only Fortune 500s. Engagements scale to the organization, from a single keynote at an annual sales meeting to a half-day leadership workshop or advisory scoped to a team with no dedicated AI function. Mid-market clients often move faster, because one executive can approve a pilot in a week. Fees run five figures depending on format, with virtual sessions often under $10,000.
.svg)
